Jenburkt Pharmaceuticals Ltd. (BSE: 524731) is a Mumbai, Maharashtra-based company in the Non-Prescription Drugs industry. With a market capitalisation of ₹433 Cr, it ranks #2,095 by market cap among the 6,197 Indian listed companies on FinBizNet, and #6 of 9 in Non-Prescription Drugs. At ₹963.05 (as of 16 Nov 2026), the share price is 10.3% below its 52-week high of ₹1,073.90 and 14.0% above its 52-week low of ₹845.00. The share price is down 11.8% over one year and down 13.0% over three months.
| Current Price | ₹963.05 |
|---|---|
| Market Cap | ₹433 Cr |
| BSE Code | 524731 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Non-Prescription Drugs |
| P/E Ratio | 12.5 |
| Return on Equity | 18.84% |
| Return on Assets | 12.59% |
| 52-Week Range | ₹845.00 – ₹1,073.90 |
| 1-Year Price Change | -11.8% |
| 3-Month Price Change | -13.0% |
| Beta (1Y) | 0.13 |
| Dividend Yield | 2.11% |
| Headquarters | Mumbai, Maharashtra |
| Website | jenburkt.com |
Delivery averaged 84.5% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. The company offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. It offers its products under the Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, Zydol Suspension, and Zixa brand names. It serves its products through stockists, doctors, pharmacies, chemists, large government, semi-government i
1. Pharmaceuticals Business-This segment offers pharmaceutical formulations.
1. Pharmaceutical Formulations-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd. | ₹44,982 Cr | 43.4 | 48.91% | ₹1,184 Cr | +3.3% |
| Alembic Pharmaceuticals Limited (Aplltd) | ₹20,245 Cr | 30.5 | 12.36% | ₹2,603 Cr | +11.7% |
| Bliss Gvs Pharma Ltd. | ₹6,817 Cr | 53.9 | 11.60% | ₹313 Cr | +426.3% |
| Zota Health Care Ltd | ₹4,585 Cr | n/m | -16.05% | ₹199 Cr | -15.1% |
| Amrutanjan Health Care Ltd. | ₹1,467 Cr | 25.3 | 16.62% | ₹135 Cr | -28.1% |
| Jenburkt Pharmaceuticals Ltd. | ₹433 Cr | 12.5 | 18.84% | — | -11.8% |
| Sat Kartar Life Limited | ₹256 Cr | 15.7 | 25.30% | — | — |
| Vista Pharmaceuticals Ltd. | ₹40 Cr | n/m | -10.82% | — | -37.1% |
| Welcure Drugs & Pharmaceuticals | ₹23 Cr | n/m | -5.50% | — | -64.2% |
Listed by market capitalisation. Ratios are shown for context only.
Jenburkt Pharmaceuticals Ltd. is trading at ₹963.05, with a market capitalisation of ₹433 Cr.
Jenburkt Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).
Jenburkt Pharmaceuticals Ltd. has a P/E of 12.5 and a return on equity of 18.84%.
Jenburkt Pharmaceuticals Ltd. is listed on the BSE under the scrip code 524731.
Jenburkt Pharmaceuticals Ltd.'s share price is down 11.8% over one year and down 13.0% over three months. Its 52-week range is ₹845.00 to ₹1,073.90.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.